Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.
Xinyu Nan, MD
Advertisement
Articles by Xinyu Nan, MD
Advertisement
Latest Updated Articles
Immunotherapeutic Approaches to the Management of Head and Neck CancerPublished: December 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Early Detection, Education Are Key to Combat Rising Pancreatic Cancer Cases
2
Examining Developments in Safe Administration of Nuclear Agents
3
FDA Approves Durvalumab Plus FLOT in Resectable Gastric/GEJ Cancers
4
Sonrotoclax Earns FDA Priority Review in R/R Mantle Cell Lymphoma
5
